Crescendo Biologics Ltd: Crescendo Biologics Expands its Ongoing Collaboration with Takeda Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T cell enhancing therapeutics, today announced that it has expanded its global, multi-target discovery and development collaboration with Takeda Pharmaceutical Company Limited (Takeda) after Crescendo achieved its sixth technical milestone. Under its ongoing collaboration and license agreement, Crescendo's proprietary transgenic platform and engineering expertise is being used to build Humabody -based therapeutics against certain targets selected by Takeda. The collaboration expansion gives Takeda access to a range of Crescendo's half-life extension Humabodies for use with its two Humabody programmes, previously licensed in November 2018 and July 2019, and Humabody programmes Takeda licenses in the future during the term of the collaboration expansion.